Arvinas announces FDA clearance to continue with ARV-110 IND

Arvinas announced that the FDA has cleared the company’s investigational new drug application, or IND, for ARV-110, an oral androgen receptor Protac protein degrader, for the treatment of patients with metastatic castration-resistant prostate cancer, or mCRPC. Arvinas expects to begin enrollment of a Phase 1 clinical trial for ARV-110 in Q1. The Phase 1 study will investigate the safety and tolerability of ARV-110 in patients with mCRPC who have progressed on at least two standard of care treatment regimens and includes exploratory measures of efficacy.
https://thefly.com/landingPageNews.php?id=2844079